Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC

Seth A. Brodie, Courtney Lombardo, Ge Li, Jeanne Kowalski, Khanjan Gandhi, Shaojin You, Fadlo R. Khuri, Adam Marcus, Paula M. Vertino, Johann C. Brandes

Research output: Contribution to journalArticle

Abstract

Conclusions: CAV1 methylation is a predictor of disease stabilization and improved overall survival following chemotherapy with a taxane-platinum combination regimen in advanced NSCLC. CAV1 methylation may predict improved outcomes for other chemotherapeutic agents which are subject to cellular clearance mediated by caveolae.

Methods: We studied a cohort of 49 patients (median age 62 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. Methylation analysis was done on the Illumina GoldenGate Cancer panel 1 methylation microarray platform. Methylation data were correlated with clinical response and adjusted for false discovery rates.

Purpose: Aberrant promoter DNA methylation can serve as a predictive biomarker for improved clinical responses to certain chemotherapeutics. One of the major advantages of methylation biomarkers is the ease of detection and clinical application. In order to identify methylation biomarkers predictive of a response to a taxane-platinum based chemotherapy regimen in advanced NSCLC we performed an unbiased methylation analysis of 1,536 CpG dinucleotides in cancerassociated gene loci and correlated results with clinical outcomes.

Results: Cav1 methylation emerged as a powerful predictor for achieving disease stabilization following platinum taxane based chemotherapy (p = 1.21E-05, FDR significance = 0.018176). In Cox regression analysis after multivariate adjustment for age, performance status, gender, histology and the use of bevacizumab, CAV1 methylation was significantly associated with improved overall survival (HR 0.18 (95%CI: 0.03-0.94)). Silencing of CAV1 expression in lung cancer cell lines(A549, EKVX)by shRNA led to alterations in taxane retention.

Original languageEnglish (US)
Article numbere107124
JournalPLoS One
Volume9
Issue number9
DOIs
StatePublished - Sep 15 2014
Externally publishedYes

Fingerprint

taxanes
Caveolin 1
platinum
Methylation
Chemotherapy
Combination Drug Therapy
Platinum
methylation
drug therapy
promoter regions
Biomarkers
biomarkers
Drug Therapy
Stabilization
taxane
Caveolae
Histology
Survival
DNA methylation
DNA Methylation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC. / Brodie, Seth A.; Lombardo, Courtney; Li, Ge; Kowalski, Jeanne; Gandhi, Khanjan; You, Shaojin; Khuri, Fadlo R.; Marcus, Adam; Vertino, Paula M.; Brandes, Johann C.

In: PLoS One, Vol. 9, No. 9, e107124, 15.09.2014.

Research output: Contribution to journalArticle

Brodie, SA, Lombardo, C, Li, G, Kowalski, J, Gandhi, K, You, S, Khuri, FR, Marcus, A, Vertino, PM & Brandes, JC 2014, 'Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC', PLoS One, vol. 9, no. 9, e107124. https://doi.org/10.1371/journal.pone.0107124
Brodie, Seth A. ; Lombardo, Courtney ; Li, Ge ; Kowalski, Jeanne ; Gandhi, Khanjan ; You, Shaojin ; Khuri, Fadlo R. ; Marcus, Adam ; Vertino, Paula M. ; Brandes, Johann C. / Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC. In: PLoS One. 2014 ; Vol. 9, No. 9.
@article{bd5bd10c79154e3da0c793faa237b521,
title = "Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC",
abstract = "Conclusions: CAV1 methylation is a predictor of disease stabilization and improved overall survival following chemotherapy with a taxane-platinum combination regimen in advanced NSCLC. CAV1 methylation may predict improved outcomes for other chemotherapeutic agents which are subject to cellular clearance mediated by caveolae.Methods: We studied a cohort of 49 patients (median age 62 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. Methylation analysis was done on the Illumina GoldenGate Cancer panel 1 methylation microarray platform. Methylation data were correlated with clinical response and adjusted for false discovery rates.Purpose: Aberrant promoter DNA methylation can serve as a predictive biomarker for improved clinical responses to certain chemotherapeutics. One of the major advantages of methylation biomarkers is the ease of detection and clinical application. In order to identify methylation biomarkers predictive of a response to a taxane-platinum based chemotherapy regimen in advanced NSCLC we performed an unbiased methylation analysis of 1,536 CpG dinucleotides in cancerassociated gene loci and correlated results with clinical outcomes.Results: Cav1 methylation emerged as a powerful predictor for achieving disease stabilization following platinum taxane based chemotherapy (p = 1.21E-05, FDR significance = 0.018176). In Cox regression analysis after multivariate adjustment for age, performance status, gender, histology and the use of bevacizumab, CAV1 methylation was significantly associated with improved overall survival (HR 0.18 (95{\%}CI: 0.03-0.94)). Silencing of CAV1 expression in lung cancer cell lines(A549, EKVX)by shRNA led to alterations in taxane retention.",
author = "Brodie, {Seth A.} and Courtney Lombardo and Ge Li and Jeanne Kowalski and Khanjan Gandhi and Shaojin You and Khuri, {Fadlo R.} and Adam Marcus and Vertino, {Paula M.} and Brandes, {Johann C.}",
year = "2014",
month = "9",
day = "15",
doi = "10.1371/journal.pone.0107124",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC

AU - Brodie, Seth A.

AU - Lombardo, Courtney

AU - Li, Ge

AU - Kowalski, Jeanne

AU - Gandhi, Khanjan

AU - You, Shaojin

AU - Khuri, Fadlo R.

AU - Marcus, Adam

AU - Vertino, Paula M.

AU - Brandes, Johann C.

PY - 2014/9/15

Y1 - 2014/9/15

N2 - Conclusions: CAV1 methylation is a predictor of disease stabilization and improved overall survival following chemotherapy with a taxane-platinum combination regimen in advanced NSCLC. CAV1 methylation may predict improved outcomes for other chemotherapeutic agents which are subject to cellular clearance mediated by caveolae.Methods: We studied a cohort of 49 patients (median age 62 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. Methylation analysis was done on the Illumina GoldenGate Cancer panel 1 methylation microarray platform. Methylation data were correlated with clinical response and adjusted for false discovery rates.Purpose: Aberrant promoter DNA methylation can serve as a predictive biomarker for improved clinical responses to certain chemotherapeutics. One of the major advantages of methylation biomarkers is the ease of detection and clinical application. In order to identify methylation biomarkers predictive of a response to a taxane-platinum based chemotherapy regimen in advanced NSCLC we performed an unbiased methylation analysis of 1,536 CpG dinucleotides in cancerassociated gene loci and correlated results with clinical outcomes.Results: Cav1 methylation emerged as a powerful predictor for achieving disease stabilization following platinum taxane based chemotherapy (p = 1.21E-05, FDR significance = 0.018176). In Cox regression analysis after multivariate adjustment for age, performance status, gender, histology and the use of bevacizumab, CAV1 methylation was significantly associated with improved overall survival (HR 0.18 (95%CI: 0.03-0.94)). Silencing of CAV1 expression in lung cancer cell lines(A549, EKVX)by shRNA led to alterations in taxane retention.

AB - Conclusions: CAV1 methylation is a predictor of disease stabilization and improved overall survival following chemotherapy with a taxane-platinum combination regimen in advanced NSCLC. CAV1 methylation may predict improved outcomes for other chemotherapeutic agents which are subject to cellular clearance mediated by caveolae.Methods: We studied a cohort of 49 patients (median age 62 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. Methylation analysis was done on the Illumina GoldenGate Cancer panel 1 methylation microarray platform. Methylation data were correlated with clinical response and adjusted for false discovery rates.Purpose: Aberrant promoter DNA methylation can serve as a predictive biomarker for improved clinical responses to certain chemotherapeutics. One of the major advantages of methylation biomarkers is the ease of detection and clinical application. In order to identify methylation biomarkers predictive of a response to a taxane-platinum based chemotherapy regimen in advanced NSCLC we performed an unbiased methylation analysis of 1,536 CpG dinucleotides in cancerassociated gene loci and correlated results with clinical outcomes.Results: Cav1 methylation emerged as a powerful predictor for achieving disease stabilization following platinum taxane based chemotherapy (p = 1.21E-05, FDR significance = 0.018176). In Cox regression analysis after multivariate adjustment for age, performance status, gender, histology and the use of bevacizumab, CAV1 methylation was significantly associated with improved overall survival (HR 0.18 (95%CI: 0.03-0.94)). Silencing of CAV1 expression in lung cancer cell lines(A549, EKVX)by shRNA led to alterations in taxane retention.

UR - http://www.scopus.com/inward/record.url?scp=84907149050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907149050&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0107124

DO - 10.1371/journal.pone.0107124

M3 - Article

C2 - 25222296

AN - SCOPUS:84907149050

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e107124

ER -